Stem Cells to Prevent and Reverse Disability in Multiple Sclerosis

Associate Professor Tomas Kalincik

Professor Tomas Kalincik

University of Melbourne, VIC

| A cure via repair and regeneration | Immunology | Project | 2023 | Investigator Led Research |


Chemotherapy with autologous hematopoietic stem cell transplantation (AHSCT) is occasionally being used to treat aggressive forms of multiple sclerosis (MS). However, it is unclear how its effectiveness compares to standard MS therapies.  

In this project, Professor Kalincik will use one of the largest international datasets to compare the effectiveness of stem cell transplantation with the most effective MS therapies.  

The project will compare treatment outcomes in AHSCT vs. B-cell depleting therapies (ocrelizumab, rituximab) and immune reconstitution therapy (cladribine).  

The team will also explore individual determinants of response to AHSCT. Finally, they will compare different AHSCT conditioning regimens.  

This knowledge will enable informed use of stem cell transplantation in the treatment of MS. 

Updated: 22 February, 2023

Stages of the research process

Fundamental laboratory

Laboratory research that investigates scientific theories behind the possible causes, disease progression, ways to diagnose and better treat MS.

Lab to clinic timeline: 10+ years

Research that builds on fundamental scientific research to develop new therapies, medical procedures or diagnostics and advances it closer to the clinic.

Lab to clinic timeline: 5+ years
Clinical Studies
and Clinical Trials

Clinical research is the culmination of fundamental and translational research turning those research discoveries into treatments and interventions for people with MS.

Lab to clinic timeline: 1-5 years
Read More

Newsletter subscription

  • Enter your details

Stem Cells to Prevent and Reverse Disability in Multiple Sclerosis